Hum­ming­bird and Synaf­fix agree to an­ti­body-drug con­ju­gate deal worth up to $150M

The Dutch biotech Synaf­fix has been ac­tive on the deal front for the past few years. And it’s not show­ing signs of stop­ping, hit­ting the ground run­ning in 2023 by ink­ing a deal with Sin­ga­pore’s Hum­ming­bird Bio­science.

In an an­nounce­ment Mon­day, Hum­ming­bird and the an­ti­body-drug con­ju­gate biotech said they will en­ter in­to a li­cens­ing agree­ment, open­ing the door for Hum­ming­bird to de­vel­op an ADC pro­gram us­ing Synaf­fix’s tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER